Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
VectivBio logo — Biotech company develops treatments for severe rare diseases...

VectivBio

Biotech company develops treatments for severe rare diseases, aims to become global leader with patient-centric approach.

Founded 2019 Switzerland Basel, Switzerland 57 employees Acquired Total: $1.29B Biotechnology, Health Care

General Information

Company Name VectivBio
Founded Year 2019
Location Switzerland Basel, Switzerland +1
Founders / Decision Makers
Team member Team member Team member
Employees 57
Industries Biotechnology, Health Care
Funding Stage Acquired
Social

Get notified when VectivBio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About VectivBio

VectivBio is a Switzerland-based clinical-stage biotech company founded in 2019, focused on developing treatments for severe rare diseases. With a clear emphasis on a patient-centric approach, their mission is to address significant unmet medical needs by developing life-changing therapies.

The company boasts a skilled team with a proven track record in research, development, commercialization, and business growth. By aiming to become a global leader in the biotechnology and healthcare industries, VectivBio is committed to advancing novel therapies for orphan conditions with substantial medical requirements.

The company recently attracted a notable $1.00B acquisition investment from Ironwood Pharmaceuticals on 01 May 2023. This substantial investment underscores confidence in VectivBio's potential and strategic direction in the competitive biotech landscape.

Taxonomy: Rare Diseases, Clinical-Stage Biotech, Patient-Centric Approach, Orphan Conditions, Drug Development, Therapy Commercialization, Innovative Medicines, Spinout Company, Translational Research, Life-Changing Therapies, Severe Illnesses, Targeted Therapies, Medical Needs

Services & Products

GI Treatment Advancement
Pharmaceutical Development
Patient Outcome Improvement
Research & Development

Target Customers

GI Patients Healthcare Providers Hospitals Medical Researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition •••••• 1 •••• •••• 01 May 2023
Post Ipo Equity •••••• 1
Investor
01 Jul 2022
Post Ipo Debt •••••• 1
Investor
01 Mar 2022
IPO •••••• - 01 Apr 2021
Early VC •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		01 Oct 2020

View All 6 Funding Rounds

VectivBio Alternatives & Competitors

View All Alternatives
VectivBio vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Compare VectivBio vs Taysha Gene Therapies
VectivBio vs
Ambros Therapeutics
Ambros Therapeutics United States

Seeking a potential breakthrough therapy for patients suffering from Complex Regional Pain Syndrome...

32 employees
VectivBio vs
Neuvasq Biotechnologies
Neuvasq Biotechnologies Belgium

Advancing neurological therapies to safeguard or rebuild CNS barriers and ameliorate neurovascular f...

Series A
13 employees
Biotechnology, Pharmaceutical
Compare VectivBio vs Neuvasq Biotechnologies
Also compare with: VectivBio vs CureGRIN Foundation CureGRIN Foundation View all alternatives

FAQ About VectivBio

Biotech company develops treatments for severe rare diseases, aims to become global leader with patient-centric approach.
VectivBio was founded in 2019.
VectivBio is headquartered in Basel, Switzerland.
VectivBio operates in the following industries: Biotechnology, Health Care.
VectivBio has approximately 57 employees.
VectivBio has completed 6 funding rounds, raising a total of $1.29B. The latest funding stage is Acquired.
VectivBio offers: GI Treatment Advancement, Pharmaceutical Development, Patient Outcome Improvement, Research & Development.
Top alternatives and competitors to VectivBio include Taysha Gene Therapies, Ambros Therapeutics, Neuvasq Biotechnologies, Priovant Therapeutics, CureGRIN Foundation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VectivBio and Taysha Gene Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors VectivBio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy